Pfizer Vfend Sets New Efficacy Standard In Invasive Aspergillosis, FDA Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Vfend’s marked efficacy in invasive aspergillosis makes the Pfizer antifungal attractive as an active comparator in studies for the indication, FDA review documents suggest.